Copyright
©The Author(s) 2021.
World J Exp Med. Mar 20, 2021; 11(2): 17-29
Published online Mar 20, 2021. doi: 10.5493/wjem.v11.i2.17
Published online Mar 20, 2021. doi: 10.5493/wjem.v11.i2.17
n | Mean | SD | Mean rank | χ2 | df | P value | |
Pre-test | 8 | 21.63 | 2.83 | 5.75 | 38.741 | 5 | 0.000 |
Post-test 1 wk | 8 | 19.50 | 3.21 | 5.066 | |||
Post-test 1 mo | 8 | 17.75 | 2.96 | 4.06 | |||
Post-test 2 mo | 8 | 16.38 | 3.02 | 3.13 | |||
Post-test 4 mo | 8 | 13.88 | 3.40 | 1.94 | |||
Post-test 12 mo | 8 | 12.13 | 3.64 | 1.06 |
- Citation: Kabataş S, Civelek E, Kaplan N, Savrunlu EC, Sezen GB, Chasan M, Can H, Genç A, Akyuva Y, Boyalı O, Diren F, Karaoz E. Phase I study on the safety and preliminary efficacy of allogeneic mesenchymal stem cells in hypoxic-ischemic encephalopathy. World J Exp Med 2021; 11(2): 17-29
- URL: https://www.wjgnet.com/2220-315x/full/v11/i2/17.htm
- DOI: https://dx.doi.org/10.5493/wjem.v11.i2.17